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Abstract
Multiple single nucleotide polymorphisms (SNPs) have been identified in the tumor suppressor gene p53, though the
relevance of many of them is unclear. Some of them are also differentially distributed in various ethnic populations,
suggesting selective functionality. We have therefore sequenced all exons and flanking regions of p53 from the Singaporean
Chinese population and report here the characterization of some novel and uncharacterized SNPs - four in intron 1
(nucleotide positions 8759/10361/10506/11130), three in intron 3 (11968/11969/11974) and two in the 39UTR (19168/
19514). Allelic frequencies were determined for all these and some known SNPs, and were compared in a limited scale to
leukemia and lung cancer patient samples. Intron 2 (11827) and 7 (14181/14201) SNPs were found to have a high minor
allele frequency of between 26–47%, in contrast to the lower frequencies found in the US population, but similar in trend to
the codon 72 polymorphism (SNP12139) that shows a distribution pattern correlative with latitude. Several of the SNPs were
linked, such as those in introns 1, 3 and 7. Most interestingly, we noticed the co-segregation of the intron 2 and the codon
72 SNPs, the latter which has been shown to be expressed in an allele-specific manner, suggesting possible regulatory cross-
talk. Association analysis indicated that the T/G alleles in both the co-segregating intron 7 SNPs and a 4tagSNP haplotype
was strongly associated increased susceptibility to lung cancer in non-smoker females [OR: 1.97 (1.32, 3.394)]. These data
together demonstrate high SNP diversity in p53 gene between different populations, highlighting ethnicity-based
differences, and their association with cancer risk.
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Introduction
The tumor-suppressor gene p53 is highly mutated up to 50% in
all human cancer types [1], making it the most genetically targeted
gene involved in carcinogeneis. Mutations often lead to loss of the
tumor-suppressive functions of p53 - especially the transcription-
dependent functions, highlighted by the enormous hot-spot
mutations in the DNA-binding domain - thereby leading to
uncontrolled cellular growth [1–3]. Besides mutations, p53 is
thought also to be functionally inactivated through deregulated
upstream and downstream regulators [1–3]. A case in point is the
overexpression of its negative regulator MDM2, which leads to the
rapid degradation of p53 [4–6]. In addition, p53 can also be
functionally incapacitated by altered activation mechanisms
involving post-translational modifications [7,8]. p53 therefore is
not mutated in these cases but is unable to perform its functions
optimally due to lack of activation, as has also been noted in the
case of neuroblastomas where it is often sequestered in the
cytoplasm [9].
Being the most important tumor suppressor gene, the
association of p53 status with cancer risk has always been a
captivating area of work. As mutations do not lead to elevated
non-familial cancer risk in population-based studies (except in the
Li-Fraumeni syndrome families with germ-line p53 mutations), the
role of single nucleotide polymorphisms (SNPs) in p53 and their
association with cancer risk has been studied extensively. It is
noteworthy that there are about 90 SNPs reported in the p53 gene,
of which only six are in coding exons [10]. The relevance of the
majority of the intronic SNPs is at present unclear. However, a few
of the intronic SNPs, in particular, those in intron 3 (SNP11951)
and intron 6 (SNP13494 and 13964) has been associated with
cancer predisposition [11–14]. Nonetheless, the functional rele-
vance of the different intronic SNPs in affecting cancer risk is not
well understood. Moreover, most of the other intronic SNPs have
not been well characterized, or little information including allelic
frequency in various populations is available to understand their
significance. Of the exonic SNPs, only two, in exon 4, are non-
synonymous SNPs leading to altered amino-acids (SNP12063
encoding for codon 47 and SNP12139 coding for codon 72) [15].
Both these polymorphisms have been suggested to affect p53
function to varying extents, though the relevance of the codon 72
polymorphism has been extensively studied over the last 2 decades
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associated with cancer risk in many cases. Essentially, both the G
(giving rise to an arginine amino-acid) or C (giving rise to a proline
amino-acid) alleles have been found to be associated with various
types of cancer risks, though such associations have not been
consistently noted in different populations [17–26]. Interestingly,
there is a clear trend in the distribution of these polymorphic
alleles, and a correlation exists between the presence of the G allele
and distance away from the Equator [27]. Therefore, populations
such as the Africans who live closer to the Equator tend to have a
larger proportion of C-allele carriers compared to the Northern
Europeans who are predominantly the G-allele carriers [27].
Thus, ethnicity has been suggested to be a critical factor in
determining the effects of these different alleles on cancer
predisposition [18,20,23], underlining the need for understanding
the allelic distribution in various populations.
Functionally, the different codon 72 polymorphic variants have
been shown to affect p53 function differentially. The arginine-
variant was found to have a higher ability to induce mitchondrial-
mediated apoptosis [28]. In contrast, the proline-variant was found
to have a bettercapacityto induceDNA-repairand cell-cyclearrest,
by virtue of differential activation of p53-target genes [29,30].
Moreover, these variants have differing affinities to protein partners
such as iASPP and MDM2 [28,31], thereby suggesting that the
structural changes may influence the function of these p53 forms.
We have previously reported that there is an allele-specific
expression of the codon72-polymorphic variant p53 forms, both in
heterozygous normal and cancer cohorts [17]. In normal healthy
individuals, the proline-variant was preferentially expressed in
contrast to the preferential expression of the arginine-variant in
the breast cancer heterozygote cases [17]. How this allele-specific
expression is regulated is unclear. Thus, in an attempt to
investigate if there are other regulatory regions that may have
relevance to this allele-specific expression, we embarked on
sequencing the p53 gene locus to identify polymorphisms that
may be linked to the codon 72 polymorphism, as well as to identify
novel SNPs and to characterize the frequency of some of the SNPs
in the Chinese population, since population-based variations in
allele frequencies have been demonstrated for p53 SNPs [27].
Here we report the characterization of several novel and already
known SNPs in the Chinese population, and note an ethnicity-
based association of some SNP alleles that are predominant in the
Chinese population compared to the US population (which
comprises of 24 African Americans, 24 Asian Americans, 24
European Americans, 12 Hispanic American, 6 Native Ameri-
cans). Moreover, we show the complete linkage of an intron 2 SNP
with the codon 72 polymorphism, suggesting that this SNP pair
may have relevance in determining the preferential expression of
the codon 72 polymorphic variants. Finally, we also noted
association of the intron 7 SNPs with cancer risk, both alone or
in the haplotype analysis in a limited scale study of female non-
smoker lung-cancer samples. Detailed results are presented.
Results
Identification of novel SNPs in p53 and their allelic
frequencies
We sequenced the regions covering all the exons and their
flanking regions of the p53 gene of about 11 kb from genomic
DNA of healthy volunteers, from intron 1 (from nucleotide
position 8634) to the 39UTR region (19715), and identified several
intronic SNPs that have not been previously reported or have been
reported but not characterized. These included four in intron 1 (at
positions 8759, 10361, 10506 and 11130), three in intron 3 (11968,
11969 and 11974) and two in the 39UTR (19168 and 19514).
Comparison with HapMap data indicated that of these, one SNP
in intron 1 (10506) and all three in intron 3 (11968, 11969 and
11974) have not been previously reported. Table 1 shows the
SNPs in p53 that we identified, together with some of the others
that are already known and is the subject of this study. The SNP
alleles specifically characterized in this study are as follows: in
intron 1 - 8759T/C, 10361G/A, 10506T/C and 11130A/G;
intron 3 – 11968G/A, 11969G/C and 11974G/A; 39UTR –
19168G/A and 19514G/A.
Table 1. List of SNPs analyzed among Chinese healthy controls.
SNP
(Intron/exon …nucleotide
position) Minor allele Major allele
Minor allele
frequency (95% CI)
Minor allele frequency
from HapMap
(US population)
Minor allele frequency
from HapMap
(Chinese population)
In.1….8759 C T 0.292 (0.214, 0.385) 0.19 Not reported
In.1….10361 A G 0.311 (0.231, 0.404) 0.29 Not reported
In.1….10506 C T 0.274 (0.198, 0.366) Not reported Not reported
In.1. …11130 A G 0.292 (0.214, 0.385) 0.17 Not reported
In.2….11827 C G 0.470 (0.355, 0.589) 0.25 Not reported
In.3….11968 A G 0.009 (0.002, 0.051) Not reported Not reported
In.3….11969 C G 0.009 (0.002, 0.051) Not reported Not reported
In.3….11974 A G 0.009 (0.002, 0.051) Not reported Not reported
In.3….11992 A C 0.029 (0.010, 0.082) 0.05 Not reported
Ex.4….12139 C G 0.470 (0.355, 0.589) 0.35 0.50
In.6….13494 A G 0.028 (0.01, 0.079) 0.06 0.034
In.7….14181 T C 0.264 (0.189, 0.355) 0.16 Not reported
In.7….14201 G T 0.264 (0.189, 0.355) 0.083 0.39
39UTR..19168 A G 0.117 (0.067, 0.197) 0.10 0.044
39UTR..19514 A G 0.052 (0.022, 0.116) 0.04 Not reported
doi:10.1371/journal.pone.0015320.t001
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known SNPs were determined using samples from healthy Chinese
population [17] (Table 1). All SNPs in controls were in Hardy-
Weinberg Equilibrium. Minor allele frequencies (MAF) of each
SNP, together with 95% CI are listed in Table 1. Among these 15
SNPs analyzed (including the novel ones), three SNPs at intron 3
(11968, 11969, 11974) had MAF of less than 1%. Of the
remaining 12 SNPs, the MAF ranges from 2.8% (SNP 13494) to
47.0% (11827 and 12139 [codon 72]). Of note, several SNPs in
introns 1, 2 and 7 had MAF between 26–46%, in contrast to lower
frequencies reported in the US population [10], suggesting that
these SNPs may have important functional relevance in p53
biology in a population-dependent manner.
Co-segregating SNPs
Of the newly characterized SNPs, several of them co-
segregated. The pattern of pairwise linkage disequilibrium (LD)
between the various SNPs among controls are shown in Figure 1.
For example, the intron 1 SNPs 8759T/C co-segregated with SNP
10361G/A (1602 nucleotides apart) and SNP 10506T/C (1747
nucleotides apart) (Figure 1). The SNPs at position 8759, 10361
and 10506 in intron 1 were in strong LD to each other with r
2
greater than 0.8. Similarly, the three SNPs in intron 3 including
SNP11968, 11969 and 11974 were in complete LD to each other
(all r
2=1) (Figure 1).
We also identified a linkage between previously noted SNPs,
such as that in intron 7 (32). The two SNPs in intron 7 (14181 and
14201) were also in complete LD (r
2 equal to 1). Moreover, we also
found that the SNP in intron 2 (11827) co-segregated with the
common codon 72 polymorphic SNP12139 in exon 4 (Figure 1). A
noteworthy point is that the intervening coding regions, which
contain the SNPs in intron 3, were not linked with these alleles.
Moreover, the intron 7 SNPs have some level of LD with the
intron 1 and 2 SNPs (r
2.0.6), though the intervening SNP13494
site in intron 6 was not linked with them, highlighting gene
rearrangements in the p53 gene. Thus, the data analyses have
uncovered previously unnoticed LD associations, especially
between the intron 2 SNP11827 and the codon 72 SNP12139,
the latter which has been associated with cancer predisposition
[19,21,22,25,26].
SNPs and association with cancer susceptibility
In order to determine if the newly identified SNPs have any
association with cancer susceptibility, we analyzed the distribution
of some of the alleles of the SNPs in healthy normal donors, and in
a pilot study with a small group of leukemia patients or in a group
of non-smoker female lung cancer patients, which have been used
in our previous p53 association studies. The leukemia group
analyzed consisted of up to 44 Chinese patients whose DNA were
previously used for analysis of the effect of p53 codon 72
polymorphism (in exon 4), which revealed no significant
association of this polymorphism on leukemia susceptibility [33].
The lung cancer cohort consisted of up to 79 patient samples, also
utilized in a previous study analyzing the effects of p53 codon 72
Figure 1. Graph showing pairwise r
2 linkage disequilibrium (LD). Squares in red with no numerical indicates complete LD between
markers.
doi:10.1371/journal.pone.0015320.g001
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#) for leukemia for individual SNP.
Intron/Exon…SNP Model Controls Cases OR (95% CI) GlobalP P trend
n% n%
In.3…11968 Genotype 1.000 0.349
AA 0 0.0 0 0.0
AG 1 1.9 0 0.0 0.376 (0.015, 9.465)
GG 52 98.1 44 100.0 -
Allele 1.000
A 1 0.9 0 0.0 0.380 (0.015, 9.447)
G 105 99.1 88 100.0 -
In.3…11969 Genotype 1.000 0.349
CC 0 0.0 0 0.0
CG 1 1.9 0 0.0 0.376 (0.015, 9.465)
GG 52 98.1 44 100.0 -
Allele 1.000
C 1 0.9 0 0.0 0.380 (0.015, 9.447)
G 105 99.1 88 100.0 -
In.3…11974 Genotype 1.000 0.349
AA 0 0.0 0 0.0
AG 1 1.9 0 0.0 0.376 (0.015, 9.465)
GG 52 98.1 44 100.0 -
Allele 1.000
A 1 0.9 0 0.0 0.380 (0.015, 9.447)
G 105 99.1 88 100.0 -
In.3…11992 Genotype 1.000 0.750
AA 0 0.0 0 0.0
AC 3 5.8 2 4.5 0.742 (0.119, 4.651)
CC 49 94.2 42 95.5 -
Allele 1.000
A 3 2.9 2 2.3 0.748 (0.122, 4.579)
C 101 97.1 86 97.7 -
In.6…13494 Genotype 0.675 0.570
AA 0 0.0 0 0.0
AG 3 5.7 3 8.8 1.613 (0.306, 8.498)
GG 50 94.3 31 91.2 -
Allele 0.680
A 3 2.8 3 4.4 1.585 (0.310, 8.089)
G 103 97.2 65 95.6 -
In.7…14181 Genotype 0.641 0.435
TT 4 7.5 2 8.7 1.450 (0.230, 9.160)
TC 20 37.7 11 47.8 1.595 (0.570, 4.461)
CC 29 54.7 10 43.5 -
Allele 0.440
T 28 26.4 15 32.6 1.348 (0.635, 2.861)
C 78 73.6 31 67.4 -
In.7…14201 Genotype 0.641 0.435
GG 4 7.5 2 8.7 1.450 (0.230, 9.160)
GT 20 37.7 11 47.8 1.595 (0.570, 4.461)
TT 29 54.7 10 43.5 -
Allele 0.440
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association of the codon 72 SNP with lung cancer susceptibility in
female [34].
Association tests of each SNP showed that none of the analyzed
SNPs were associated with leukemia risk (Table 2), while 2 of 6
SNPs (14181 and 14201) investigated were found to have
significant association with increased lung cancer risk (Table 3).
Based on the LD pattern among the 6 SNPs investigated in lung
cancers with MAF at least 1%, 4 tagSNPs (SNPs 11827, 11992,
13494 and 14201) were selected for further haplotype analyses. The
two most common haplotypes were GCGT (lung cancer: 58.6%,
control: 64.7%)and CCGG (case: 23.8%, control:26.1%) (Table 4).
Single omnibus test detected a significant association of these
haplotype with lung cancer (p=0.036). Further haplotype-specific
test showed that haplotype GCGG increased lung cancer risk
significantly (p=0.015) when compared to the other haplotypes
(Table 4). Similar analysis of leukemia patients did not reveal any
evidence of association with leukemia (data not shown).
These data together indicate that intron 7 SNPs 14181 and
14201 show an association with lung cancer risk in the Chinese
female non-smoker population. Moreover, the haplotype analyses
also indicate a correlation between the 4 tagSNP and increased
lung cancer probability, highlighting that intronic SNPs may play
a role in cancer susceptibility.
Intron 7 SNPs and overall survival
We therefore performed Kaplan-Meier analysis to determine if
the different genotypes of the intron 7 SNPs would affect overall
survival (OS). Median OS were found to be 1.69, 0.62 and 0.93
years for lung cancer patients with genotype C/C, C/T and T/T
at SNP 14181, respectively (Figure 2A), while it was 0.93, 0.70 and
1.69 years for patients with genotypes G/G, G/T and T/T at
SNP14201, respectively (Figure 2B). Log-rank tests did not detect
any significant difference in OS among different genotypes at
SNPs14181 (p=0.112) and 14201 (p=0.108). These data
therefore indicate that although the intron 7 SNPs are associated
with risk of lung cancer, there are no notable associations with OS
in this limited study.
Discussion
This work was undertaken to perform a detailed analysis of
SNPs in the p53 gene in the Chinese population, with the aim of
uncovering new SNPs as well as to study previously noted SNPs in
HapMap that have not been characterized in the Chinese cohorts
[10]. Although many SNPs have been reported in the HapMap
project, most contain only data from the US population (which
comprises of 24 African Americans, 24 Asian Americans, 24
European Americans, 12 Hispanic American, 6 Native Americans)
[10]. Our analysis confirmed the presence of SNPs noted in the
HapMap project, and also uncovered several novel SNPs in
introns 1 and 3. In addition, we focused our attention on other
related and interesting SNPs, such as those in introns 2, 7 and 11,
and have identified complete LD between the known codon 72
polymorphism (SNP12139) in exon 4 and the SNP11827 in intron
2, suggesting that they may be functionally related. Furthermore,
we have noticed a strong correlation between the two linked SNPs
in intron 7 with lung cancer predisposition.
When the allelic frequencies from our study was compared to the
HapMap data on Chinese subjects, there was a general correlation,
as evidenced by the exon 4 SNP12139, intron 6 SNP13494 and
intron 7 SNP14201 (Table 1), validating this analysis. Based on this,
further comparison of reported frequencies in the US population
with the Chinese population revealed strong differences in two sets
of SNPs; the intron 2 (11827)/exon 4 (12139) and the intron 7 SNPs
(14181/14201).Essentially, thereisanincreaseofthe minorallelein
the Chinese population compared to the US population in the
above cases, similar to the originally described trend of an
association of the exon 4 (codon 72) SNP with populations at
different latitudes [27]. This therefore highlights that ethnicity is a
critical factor in the distribution of allelic frequencies, and may be
functionally relevant in determining p53 function.
Themost striking observationwasthe identification ofthelinkage
of the intron 2 SNP (11827) with the common codon 72 SNP in
exon 4 (12139), which were in complete LD with each other. It was
interesting that this was not noticed earlier, given the fact that the
codon 72 SNP has been extensively studied with respect to cancer
susceptibility. We have previously reported that the arginine or the
proline variants of the exon 4 polymorphism, which arise due to the
G or C nucleotides respectively, can be differentially expressed in
healthy and cancer cases [17]. The regulation of the allele-specific
differential expression is at present unclear. Thus, the recognition of
the linkage between this SNP and of that in intron 2, especially with
the C or G nucleotides co-segregating in both cases, may provide us
with some clues to the regulation of the codon 72 SNP-specific
expression, provided that the intron 2 SNP has transcription
Intron/Exon…SNP Model Controls Cases OR (95% CI) GlobalP P trend
n% n%
G 28 26.4 15 32.6 1.348 (0.635, 2.861)
T 78 73.6 31 67.4 -
39UTR…19168 Genotype 0.161 0.135
AA 0 0.0 0 0.0
AG 11 23.4 4 10.8 0.397 (0.115, 1.368)
GG 36 76.6 33 89.2 -
Allele 0.182
A 11 11.7 4 5.4 0.432 (0.131, 1.414)
G 83 88.3 70 94.6 -
*: OR – Odds ratio.
#: CI - confidence interval.
doi:10.1371/journal.pone.0015320.t002
Table 2. Cont.
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Moreover, the relevance of the intron 2 SNP has not been well
characterizedyet,especiallywithrespecttocancersusceptibility,but
given the recognition of complete LD with the exon 4 SNP, future
work should shed light on its functional relevance. It is also
noteworthy that the intervening SNPs in intron 3 are totally not
linked to the intron 2 and codon 72 SNPs, suggesting rearrange-
ments in the human p53 gene have not affected this SNP pair,
tempting us to speculate that this co-segregation may be important
in regulating p53 functions.
Table 3. Risk estimates (OR and 95% CI) for lung cancer for individual SNP.
SNP Model Controls Cases OR (95% CI) Global P P trend
n% n%
In.2…11827 Genotype 0.782 0.621
CC 15 28.3 16 22.5 0.782 (0.274, 2.234)
CG 27 50.9 40 56.3 1.086 (0.434, 2.722)
GG 11 20.7 15 21.1 -
Allele 0.700
C 57 53.8 72 50.7 1.131 (0.683, 1.872)
G 49 46.2 70 49.3 -
In.3…11992 Genotype 0.119 0.070
AA 0 0.0 1 4.183 (0.166, 105.695)
AC 3 5.8 6 2.800 (0.655, 11.963)
CC 49 94.2 35 -
Allele 0.066
A 3 2.9 8 3.544 (0.910, 13.806)
C 101 97.1 76 -
Ex.4…12139 Genotype 0.782 0.621
CC 15 28.3 16 22.5 0.782 (0.274, 2.234)
CG 27 50.9 40 56.3 1.086 (0.434, 2.722)
GG 11 20.7 15 21.1 -
Allele 0.700
C 57 53.8 72 50.7 1.131 (0.683, 1.872)
G 49 46.2 70 49.3 -
In.6…13494 Genotype 0.312 0.185
AA 0 0.0 0 -
AG 3 5.7 1 0.238 (0.024, 2.356)
GG 50 94.3 70 -
Allele 0.316
A 3 2.8 1 0.243 (0.0250, 2.374)
G 103 97.2 141 -
In.7…14181 Genotype 0.018 0.011
TT 4 7.5 8 2.900 (0.768, 10.949)
TC 20 37.7 41 2.973 (1.361, 6.492)
CC 29 54.7 20 -
Allele 0.021
T 28 26.4 57 1.960 (1.132, 3.394)
C 78 73.6 81 -
In.7…14201 Genotype 0.014 0.010
GG 4 7.5 8 2.900 (0.768, 10.949)
GT 20 37.7 42 3.045 (1.396, 6.641)
TT 29 54.4 20 -
Allele 0.016
G 28 26.4 58 1.970 (1.140, 3.406)
T 78 73.6 82 -
doi:10.1371/journal.pone.0015320.t003
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No Haplotype Frequency x2 P value
In.2…
11827
In.3…
11992
In.6…
13494
In.7…
14201 Case Control
1 G C G T 0.586 0.647 0.696 0.404
2 C C G G 0.238 0.261 0.124 0.725
3 G C G G 0.063 0.003 5.884 0.015
4 C C A T 0.000 0.028 2.130 0.145
5 C A G T 0.095 0.028 3.650 0.056
6 C C G T 0.019 0.032 0.317 0.573
doi:10.1371/journal.pone.0015320.t004
Figure 2. Kaplan-Meier curves of overall survival of lung cancer patients with different genotypes at intron 7, SNP14181 (A) or
SNP14201 (B).
doi:10.1371/journal.pone.0015320.g002
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susceptibility in a limited scale using samples from our previous
studies on leukemia and female non-smoker lung cancer patients
[32,33]. Many of the SNPs characterized were not found to have
any significant association with cancer risk. However, we noticed
that the variant alleles of the intron 7 SNPs were associated with
increased risk in the lung-cancer cohorts. Although these two
SNPs were noted earlier, it was not recognized that they were
completely linked [34]. Of these two SNPs, the SNP 14181 result
in an Apa1 restriction site when it is a T nucleotide, and one group
has noted an association with risk of non-small cell lung cancer
and oral neoplasm [35,36]. However, no report has analyzed the
association of SNP 14201 or both the intron 7 SNPs with cancer
risk. Moreover, when we analyzed for association of tagSNPs with
cancer susceptibility, we found that 4 tagSNPs in intron 2, 3, 6 and
7, with the GCGG haplotype increased lung cancer risk
significantly. It is noteworthy that there is no significant LD
among these 4 SNPs, but this haplotype combination, though
infrequent in the population, was a useful indicator of cancer risk.
Similar association was not apparent in our leukemia samples, and
no correlation was noted with overall survival in this study,
probably due to the sample size, or due to the differences in cancer
type. Thus, further large-scale association studies would be useful
in determining the relevance of all these SNPs with cancer
susceptibility in various cancer types.
Finally, it is worth considering that many of the SNPs in the p53
gene are in the intronic regions. Of these, at least those in introns 2,
6 and 7 show some association with cancer risk [11–14,35,36 and
this study], suggesting that these changes may influence p53
functions. How these intronic regions affect cancer risk is unclear,
but it is not inconceivable that they may contain promoter/
enhancer activity that regulates p53 levels. Moreover, these regions
may also regulate splicing of p53, resulting in the various splice
variants that are emerging as important regulators of cell survival
[37]. Hence, future work should shed light on the functional
relevance of these intronic SNPs in regulating cancer risk.
Materials and Methods
Samples
GenomicDNA wereprepared fromperipheralblood as described
by standard procedures using the Qiagen kit, from a total of 53
healthy individuals [17], and up to 44 leukemia patients [32] and up
to 79 non-smoker lung-cancer patients [33], as have been described
in our previous studies. Study was conducted informed written
consent from participants with the approval of the National Cancer
Centre Singapore and the Department of Hematology, Singapore
General Hospital ethics committees and the Institutional Review
Board of the National University of Singapore. The genomic DNA
was used for genotyping and the data on overall survival was
obtained from the hospital records with ethics approval.
Details of the leukemia and lung cancer group have been
described in our previous studies aimed at determining the
association between codon 72 polymorphism (exon 4 SNP) and
cancer susceptibility in these populations [32,33]. Essentially, all
are Chinese Singaporeans, diagnosed at any one of three major
hospitals in the country over the study period, and the
demographic, smoking and other relevant information was
obtained by in-person interview with a trained nurse, as described
[32,33].
Genotyping and Sequencing
Genomic DNA was sequenced from nucleotide position 8634 at
the 59end of p53 to nucleotide 19715 at the 39 end of p53, covering
Table 5. Primers used and PCR conditions for sequencing p53.
Region covered Forward Primer Reverse Primer PCR Conditions
In.1 to Ex.2 p53_8634F:
59-tgagctcttactgtgtgcc-39
p53_10444R:
59-tgtgtggaccagcatcttg-39
94uC, 3mins
94uC, 30s
55uC, 40s
72uC, 30s
Repeated for 30 cycles
72uC, 5mins
p53_9533F:
59-gcctgggcaacatagtga-39
p53_10444R:
59-tgtgtggaccagcatcttg-39
As for In.1 to Ex.2
p53_10367F:
59-atggcagcctttgaaagc-39
p53_11740R:
59-aggatctgactgcggctc-39
As for In.1 to Ex.2
p53_10922F:
59-gtgagacagttgttcttcc-39
p53_11740R:
59-aggatctgactgcggctc-39
As for In.1 to Ex.2
In.1 to In.4 p53_11584F:
59-tcagacactggcatggtgt-39
p53_12403R:
59-aagcctaagggtgaagagga-39
94uC, 3mins
94uC, 30s
53uC, 40s
72uC, 30s
Repeated for 30 cycles
72uC, 5mins
In.4 to In.6 p53_12974F:
59-ttctttgctgccgtgttcca-39
p53_13536R:
59-aggtcaaataagcagcagga-39
As for In.1 to Ex.2
In.6 to In.9 p53_13894F:
59-acagagcgagattccatctc-39
p53_14861R:
59-ctgatggcaaatgccccaat-39
As for In.1 to Ex.2
In.9 to In.10 p53_17523F:
59-ctcaggtactgtgtatatac-39
p53_17747R:
59-tggaatcctatggctttcca-39
As for In.1 to Ex.2
In.10 to 39UTR p53_18303F:
59-agaggttgcggtgagctg-39
p53_19715R:
59-cactctgggaggctgagac-39
As for In.1 to Ex.2
doi:10.1371/journal.pone.0015320.t005
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Primers used in the studies are detailed in Table 5. All 53 healthy
samples were used for entire sequencing, and the indicated
numbers of cancer samples available (as in Tables 2 and 3) were
used for sequencing and genotyping. The new SNP information
has been deposited in Genbank.
Statistical Analysis
The observed genotype frequencies of each SNP in the controls
were tested for Hardy-Weinberg equilibrium (HWE) using Fisher’s
exact test. The frequency of minor allele at each SNP in HWE is
reported together with 95% Confidence Interval (CI). P value on
the basis of the 3 categorical genotypes, or allele variable, and a p
trend value on the basis of the 3 level ordinal genotype variable
(0: wildtype homozygotes, 1: heterozygotes, 2: mutant homozy-
gotes) in the logistic regression model were calculated.
SNPs with minor allele frequency (MAF) of at least 1% among
control sample were used to select tagSNPs based on pairwise r
2
linkage disequilibrium (LD) map [38] using Tagger in Haploview
version 4.0 (http://www.broad.mit.edu/mpg/haploview) [39], at
a relatively stringent r
2 threshold of 0.8. Haplotype analysis of
these tagSNPs in this case-control study was carried out using
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) [40]. For
each haplotype with frequency at least 1% either in case or
control, a single omnibus test was performed to test the effects of
all these haplotypes jointly, and haplotype-specific test with 1
degree-of-freedom was also carried out for each haplotype using
PLINK by comparing this specific haplotype with all others.
Kaplan-Meier estimated overall survival (OS) was carried out
and log-rank test was used to compare the equivalence of OS
among different genotypes at the two SNPs of intron 7. Kaplan-
Meier estimated median OS were reported for each genotype at
these two SNPs. All analyses were done using R version 2.7.1
(http://www.R-project.org).
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